The simulated results compare well with clinical data from the DAISISON study of imatinib versus dasatinib in patients with newly diagnosed CML (Cortes et al., 2016) where the data corresponds to mean BCR-ABL1 transcripts, with standard deviations, adapted from Glauche et al., 2018 for patients who received imatinib (blue) or dasatinib (red). Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.